News about "Aurobindo Pharma"

Is Pharma Packaging Keeping Pace with Drug Innovation?

As therapies grow more complex, packaging is evolving beyond protection to enable drug delivery, safety, and adherence. Pharma Industrial India explores emerging technologies and innovations shaping future-ready pharma packaging.

Aurobindo Pharma | 25/08/2026 | By News Bureau

Aurobindo Pharma's Lannett Facility Completes US FDA Inspection with 4 Observations

Aurobindo Pharma’s Lannett facility in Indiana completes a US Food and Drug Administration (FDA) inspection with 4 procedural observations and will respond within the stipulated timeline.

Aurobindo Pharma | 24/08/2026 | By News Bureau

Aurobindo Pharma's Raleigh Plant Receives VAI Classification from US FDA

Aurobindo Pharma’s Raleigh plant receives Voluntary Action Indicated (VAI) classification from the US Food and Drug Administration (FDA), closing the inspection and allowing pending inhaler and dosage-form applications to progress.

Aurobindo Pharma | 17/08/2026 | By News Bureau

Aurobindo Pharma Unit Receives US FDA Warning Letter; No Impact on US Supplies

Aurobindo Pharma’s Eugia Pharma Specialities has received a US FDA warning letter for its Telangana facility, while the company said existing US supplies remain unaffected.

Aurobindo Pharma | 14/08/2026 | By News Bureau |  162

Aurobindo Pharma's Eugia Unit I Receives US FDA Warning Letter

Aurobindo Pharma’s Eugia Pharma Unit I receives a US Food and Drug Administration (FDA) Warning Letter following OAI status, with no impact on existing US supplies.

Aurobindo Pharma | 14/08/2026 | By News Bureau |  199

Aurobindo Pharma Approves Merger of Eugia Subsidiaries to Streamline Business Operations

Aurobindo Pharma has approved the merger of two step-down subsidiaries into Eugia Pharma Specialities, a move aimed at consolidating similar businesses, reducing administrative costs and strengthening operational efficiency.

Aurobindo Pharma | 07/08/2026 | By News Bureau |  111

CuraTeQ Biologics Secures ANVISA Approval for Hyderabad Biosimilars Manufacturing Facility

CuraTeQ Biologics has received ANVISA GMP approval for its Hyderabad biosimilars manufacturing facility, strengthening its global regulatory credentials and enabling expanded supply of biosimilar products to Brazil and the wider Latin American market.

Aurobindo Pharma | 22/07/2026 | By News Bureau |  149

Aurobindo Pharma USA Completes Acquisition of Lannett Company

Aurobindo Pharma USA has completed the acquisition of Lannett Company after securing approval from the US Federal Trade Commission. Effective June 29, 2026, Lannett will operate as Lannett Company LLC, with the combined entity aiming to strengthen the supply of essential medicines and enhance value for patients and customers.

Aurobindo Pharma | 30/06/2026 | By News Bureau

US FDA Classifies Aurobindo Pharma's Eugia Unit-III Inspection as Official Action Indicated

Aurobindo Pharma said the US FDA has classified its inspection of Eugia Unit-III in Telangana as Official Action Indicated, while reaffirming its commitment to maintaining global quality manufacturing standards.

Aurobindo Pharma | 16/06/2026 | By News Bureau |  241

CuraTeQ Biologics Secures CDSCO Approval for Bevqolva

CuraTeQ Biologics receives CDSCO marketing authorisation for Bevqolva, strengthening its oncology biosimilars portfolio and expanding access to advanced cancer therapies.

Aurobindo Pharma | 16/05/2026 | By News Bureau |  350